The team then showed in mice that stopping both the production and activity of CAMKK2 using sto 609, blocked the spread of prostate cancer cells and reduced the tumour size.
A prototype obesity drug called STO 609 does just that and Dr Mills thinks it could be modified to treat prostate cancer which affects 36,000 men in Britain.